Novo Nordisk shares fall 6% as company sets 2030 growth targets

Novo Nordisk shares tumbled 6% on Monday after the company outlined its growth targets through 2030. The Ozempic manufacturer saw its stock decline as the announced goals failed to excite investors who were hoping for a turnaround. The drugmaker's shares fell significantly following the disclosure of these long-term objectives, reflecting a negative market reaction to the company's strategic outlook and the specific growth targets set for the next several years within the pharmaceutical industry.